Dilated Cardiomyopathy

Table of Contents

  1. Overview
  2. Epidemiology
  3. Causes and Classification
  4. Pathophysiology
  5. Clinical Presentation
  6. Diagnosis
  7. Guideline-Directed Medical Therapy
  8. Device Therapy and Special Situations
  9. Prognosis
  10. Research Papers
  11. Connections
  12. Featured Videos

Back to Table of Contents

1. Overview

Dilated cardiomyopathy (DCM) is a primary myocardial disease characterized by ventricular chamber enlargement and impaired systolic function — specifically a left ventricular ejection fraction (LVEF) below 40% — in the absence of abnormal loading conditions (severe hypertension, valvular disease) or obstructive coronary artery disease sufficient to explain the degree of dysfunction. It is the most common cardiomyopathy worldwide, with a prevalence of approximately 1 in 2,500 individuals, and it is the leading indication for cardiac transplantation globally.

The anatomical hallmark of DCM is four-chamber enlargement, most prominently affecting the left ventricle. As the ventricle dilates, the myocardial wall paradoxically thins relative to the increased chamber radius — wall stress rises even though wall thickness is preserved or only modestly increased. The result is a large, globally hypokinetic ventricle that struggles to maintain adequate forward cardiac output. The remodeling process is not merely passive stretching; it involves profound molecular, cellular, and structural changes that progressively worsen cardiac function.

Patients typically present with the cardinal symptoms of heart failure with reduced ejection fraction (HFrEF): progressive exertional dyspnea, fatigue, orthopnea, paroxysmal nocturnal dyspnea, and peripheral edema. Left bundle branch block (LBBB) is found in approximately 25–30% of patients with DCM, reflecting the disease's predilection for disrupting the His-Purkinje conduction system. The dilated, poorly contracting left ventricle is also a potent substrate for thrombus formation — LV thrombus and systemic thromboembolism are recognized complications. Ventricular arrhythmias and sudden cardiac death (SCD) remain major causes of mortality, even in patients whose symptoms are well controlled on medical therapy.

The modern understanding of DCM has shifted substantially over the past two decades. What was once considered largely an idiopathic diagnosis is now recognized as a genetically heterogeneous disease in a substantial minority — up to 35% of cases have an identifiable genetic cause. At the same time, advances in guideline-directed medical therapy (GDMT), cardiac resynchronization therapy (CRT), and implantable cardioverter-defibrillators (ICD) have dramatically transformed the prognosis of DCM, converting what was once a rapidly fatal condition into a manageable chronic disease for most patients.

Back to Table of Contents

2. Epidemiology

DCM has an estimated prevalence of 1 in 2,500 in the general population, though this likely underestimates true prevalence given the large proportion of asymptomatic or mildly symptomatic patients who are never formally diagnosed. Incidence estimates range from 5 to 8 new cases per 100,000 persons per year in high-income countries.

Age and sex distribution: DCM demonstrates a bimodal age distribution. The first and larger peak occurs in adults aged 20–50 years — the working-age population — with a striking male predominance in idiopathic and genetic forms. Men are affected approximately 3 times more frequently than women in idiopathic DCM. A second, smaller peak occurs in the elderly, where DCM may represent the end stage of myocarditis, chronic ischemia, or long-term toxin exposure. Peripartum cardiomyopathy (PPCM) is a critical exception — it occurs exclusively in women in the peripartum period and accounts for a significant fraction of DCM diagnoses in young women.

Racial and ethnic disparities: African Americans have a higher prevalence and worse outcomes from DCM compared to White Americans. This disparity is partly explained by higher rates of hypertension and diabetes, but genetic factors also contribute. Mutations in the LMNA gene (lamin A/C) are enriched in African American populations and are associated with a particularly aggressive phenotype characterized by early atrial fibrillation, high-grade AV block, and high risk of sudden cardiac death at relatively preserved ejection fractions.

Worldwide variation: DCM occurs across all geographic regions and ethnicities. In sub-Saharan Africa, peripartum cardiomyopathy is disproportionately common, accounting for a higher fraction of all heart failure than in Western populations. Chagas cardiomyopathy — DCM caused by Trypanosoma cruzi infection — is prevalent in Latin America and is an important cause of DCM in immigrants from endemic regions living in North America and Europe. Globally, DCM remains the most common indication for heart transplantation.

Familial DCM: Population-based screening studies of first-degree relatives of DCM probands reveal abnormal echocardiographic findings — LV dilation or dysfunction — in 20–35% of relatives, defining familial DCM. Current guidelines recommend echocardiographic screening of all first-degree relatives of a DCM patient, with repeat screening every 3–5 years given the age-dependent penetrance of many DCM-causing gene mutations.

Back to Table of Contents

3. Causes and Classification

DCM is not a single disease but a final common phenotype resulting from diverse etiologies. Identifying the underlying cause has direct therapeutic and prognostic implications — some forms are reversible, some carry specific arrhythmia risks, and some require family screening. A systematic approach to etiology is essential in every new DCM diagnosis.

Genetic DCM

Genetic causes account for an estimated 25–35% of DCM cases. More than 50 causative genes have been identified, with inheritance patterns that are predominantly autosomal dominant. The major genetic causes include:

Idiopathic DCM

After excluding known genetic mutations, ischemic disease, toxins, and systemic causes, approximately 20% of DCM cases remain idiopathic. Many are believed to represent post-inflammatory DCM — subclinical viral myocarditis that resolved clinically but left permanent myocardial scarring and dysfunction. Advancing genetic testing continues to reclassify cases previously labeled idiopathic into specific genetic subtypes.

Myocarditis and Post-Viral DCM

Viral myocarditis is a well-established cause of DCM. The most implicated viruses include parvovirus B19 (which infects endothelial cells and is the most frequently detected viral genome in endomyocardial biopsies from DCM patients), enteroviruses (particularly coxsackievirus B, historically dominant), and adenoviruses. Acute myocarditis in the setting of viral infection may produce a spectrum of outcomes: complete recovery, persistent LV dysfunction (post-viral DCM), arrhythmia without structural disease, or fulminant myocarditis. The mechanisms driving post-viral DCM include direct viral cytopathic effect, immune-mediated myocardial injury by cytotoxic T cells, and autoimmune responses triggered by molecular mimicry between viral and cardiac antigens.

Peripartum Cardiomyopathy (PPCM)

PPCM is defined as new-onset LV dysfunction with LVEF <45% developing in the last month of pregnancy or within 5 months postpartum, in the absence of another identifiable cause. It is a distinct DCM subtype with its own pathophysiology: prolactin cleavage by cathepsin D produces a 16 kDa anti-angiogenic and pro-apoptotic fragment that damages the cardiac microvasculature and cardiomyocytes. PPCM has a relatively favorable prognosis — approximately 50% of patients recover LVEF to >50% within 12 months. However, recovery is unpredictable, and subsequent pregnancies carry significant risk of relapse. The dopamine agonist bromocriptine (which inhibits prolactin secretion) has been investigated as an adjunct therapy in PPCM and shown benefit in small trials.

Alcoholic DCM

Chronic heavy alcohol consumption (>8 standard drinks per day for >5 years, or equivalent cumulative exposure) is directly cardiotoxic. Ethanol and its metabolite acetaldehyde impair myocyte calcium handling, mitochondrial function, and protein synthesis, leading to ventricular dilation and dysfunction. A critical clinical point: alcoholic DCM can be substantially or completely reversible with total and sustained abstinence — LVEF recovery of 10–20 percentage points is documented with alcohol cessation. This reversibility distinguishes alcoholic DCM from most other genetic and idiopathic forms and makes complete abstinence a therapeutic intervention equivalent in importance to GDMT.

Chemotherapy-Induced Cardiomyopathy

Anthracyclines (doxorubicin, epirubicin) cause dose-dependent, largely irreversible cardiomyopathy through free radical generation, topoisomerase II inhibition, and mitochondrial injury. The risk is cumulative and dose-dependent; significant risk begins above a lifetime doxorubicin dose of 300 mg/m². Trastuzumab (Herceptin), used in HER2-positive breast cancer, causes a different form — typically reversible LV dysfunction through disruption of HER2/neuregulin signaling in cardiomyocytes. Baseline echocardiography and serial cardiac surveillance are standard of care for patients receiving cardiotoxic chemotherapy.

Thyroid and Other Metabolic Causes

Both hypothyroidism and hyperthyroidism can cause reversible cardiomyopathy. Hypothyroid cardiomyopathy produces a low-output state with pericardial effusion and bradycardia; hyperthyroid cardiomyopathy is driven by excessive heart rate and catecholamine effects with high-output failure. Nutritional deficiencies — particularly selenium deficiency (Keshan disease, reported in regions of China) and thiamine (vitamin B1) deficiency (beriberi heart disease) — cause reversible DCM that responds to supplementation. Tachycardia-induced cardiomyopathy results from persistently elevated heart rates (as in uncontrolled atrial fibrillation) and is often reversible with rate control.

Back to Table of Contents

4. Pathophysiology

Regardless of the initiating etiology, DCM progression is driven by a cascade of molecular, cellular, and neurohormonal events that collectively constitute adverse ventricular remodeling. Understanding this cascade is essential to understanding why GDMT works and what each drug class targets.

Neurohormonal Activation

The initial fall in cardiac output activates two major compensatory but ultimately maladaptive neurohormonal systems:

Ventricular Remodeling

The combination of increased wall stress, neurohormonal activation, and direct myocardial injury drives a structural transformation of the ventricle. The LV enlarges and changes shape from an ellipsoid to a more spherical geometry — a process called sphericalization. This geometric change is mechanically disadvantageous: a sphere is less efficient at generating ejection compared to an ellipse. As the LV dilates, the papillary muscles are displaced outward and apically, causing tethering and mal-coaptation of the mitral valve leaflets — producing functional (secondary) mitral regurgitation (MR) even in the absence of intrinsic mitral valve disease. Functional MR increases volume overload, further enlarges the ventricle, and creates a vicious cycle of worsening dilation and regurgitation.

Cellular Pathology

At the cellular level, DCM is characterized by:

Energy Metabolism

The failing myocardium undergoes a metabolic shift from predominantly fatty acid oxidation (the normal cardiac fuel) toward glycolysis and glucose oxidation — a fetal metabolic program that is less efficient at ATP generation. Mitochondrial dysfunction compounds this energy deficit. The net result is a heart that is simultaneously energy-starved and mechanically overloaded — explaining why even small improvements in loading conditions and heart rate (via GDMT) can produce disproportionately large improvements in function.

Back to Table of Contents

5. Clinical Presentation

DCM can present across a wide spectrum — from incidental discovery of a low ejection fraction during evaluation for an unrelated problem, to acute decompensated heart failure requiring hospital admission, to sudden cardiac death as the first manifestation. The most common presentation is a gradually progressive syndrome of heart failure with reduced ejection fraction (HFrEF).

Symptoms

The cardinal symptoms reflect the consequences of reduced cardiac output and elevated filling pressures:

Physical Examination

Key findings on physical examination reflect cardiac enlargement, elevated filling pressures, and reduced forward output:

Back to Table of Contents

6. Diagnosis

The diagnostic evaluation of DCM serves two purposes: confirming the diagnosis of LV dilation and systolic dysfunction, and systematically identifying an underlying etiology that may alter treatment or require family screening.

Echocardiography

Transthoracic echocardiography (TTE) is the primary diagnostic tool. Key findings in DCM include:

Cardiac MRI (CMR)

CMR with late gadolinium enhancement (LGE) is the most important imaging test for risk stratification and etiology in DCM. LGE patterns provide critical diagnostic and prognostic information:

Coronary Evaluation

Excluding significant obstructive coronary artery disease is mandatory in all patients presenting with new LV dysfunction, as ischemic cardiomyopathy requires revascularization rather than GDMT alone. Invasive coronary angiography remains the gold standard. CT coronary angiography is an appropriate alternative in patients with low-to-intermediate pretest probability.

Laboratory Evaluation

A systematic panel targets reversible and treatable causes:

Genetic Testing

Current guidelines recommend genetic testing for all patients with DCM who have a first-degree relative with DCM or premature sudden cardiac death, and should be considered in all patients with DCM. A positive result identifies gene-carrier family members who need surveillance echocardiograms, and in the case of LMNA mutations, specifically alters ICD thresholds and guides family screening. Multi-gene panel testing covering all known DCM-associated genes is now clinically available and cost-effective.

Holter Monitoring

24–48-hour ambulatory ECG monitoring detects NSVT, AF, and conduction abnormalities. NSVT (runs of 3 or more VT beats) is common in DCM and, in combination with an LVEF <35%, strengthens the case for ICD implantation.

Endomyocardial Biopsy (EMB)

EMB is not routinely indicated in DCM but is appropriate in specific clinical scenarios: new-onset DCM with hemodynamic compromise suggesting giant cell myocarditis (which requires immunosuppression), clinical features suggesting infiltrative disease (amyloid, sarcoidosis, hemochromatosis, Fabry disease), or active eosinophilic or hypersensitivity myocarditis. Giant cell myocarditis — a rare, fulminant form characterized by extensive giant cell infiltration and rapid progression to cardiogenic shock — carries a very poor prognosis without immunosuppression and cardiac transplantation, making timely EMB life-saving in suspected cases.

Back to Table of Contents

7. Guideline-Directed Medical Therapy (GDMT)

GDMT for DCM is one of the great success stories of modern cardiology. The combination of four drug classes — each targeting a different maladaptive pathway — has reduced mortality and hospitalization, improved symptoms, and in many patients produced substantial recovery of LVEF. The 2022 AHA/ACC/HFSA Heart Failure Guidelines now designate all four classes as Class I evidence for HFrEF:

1. ACE Inhibitors / ARBs / ARNI (Angiotensin Pathway Blockade)

ACE inhibitors (enalapril, lisinopril, ramipril) and ARBs (losartan, valsartan, candesartan) reduce Ang II-mediated vasoconstriction, fibrosis, and aldosterone release. They reduce mortality, improve symptoms, and slow disease progression. They are the cornerstone of DCM therapy since the SOLVD trials.

The angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril-valsartan (Entresto) supersedes ACEi/ARB as the preferred agent in patients who tolerate it. Sacubitril inhibits neprilysin, which degrades natriuretic peptides (BNP, ANP), augmenting their beneficial vasodilatory, diuretic, and anti-fibrotic effects while valsartan blocks the AT1 receptor. The landmark PARADIGM-HF trial (McMurray et al., 2014; PMID: 25176015) demonstrated that sacubitril-valsartan reduced the composite of cardiovascular death or HF hospitalization by 20% compared to enalapril, with a 16% reduction in all-cause mortality — a landmark result that changed the standard of care.

2. Beta-Blockers

Three beta-blockers have proven mortality benefit in HFrEF: carvedilol (non-selective beta-blocker + alpha-1 blocker), metoprolol succinate (beta-1 selective), and bisoprolol (beta-1 selective). They counteract the harmful effects of chronic sympathetic activation: reducing heart rate, myocardial oxygen demand, catecholamine-induced arrhythmias, and direct cardiomyocyte toxicity. The COPERNICUS trial of carvedilol (Packer et al., 2001; PMID: 12241719) demonstrated a 35% reduction in all-cause mortality in severe HFrEF (EF <25%). Beta-blockers must be started at very low doses and uptitrated slowly over weeks to months — acute high-dose administration in a patient with decompensated HF can precipitate further acute deterioration.

3. Mineralocorticoid Receptor Antagonists (MRA)

Spironolactone and eplerenone block aldosterone's effects on the kidney (reducing sodium retention) and the myocardium (reducing fibrosis). The RALES trial (Pitt et al., 1999; PMID: 10471456) demonstrated a 30% reduction in mortality with spironolactone in severe HFrEF. The EMPHASIS-HF trial (Zannad et al., 2011; PMID: 21073363) extended benefit to mild-to-moderate HFrEF with eplerenone, reducing the composite of death or HF hospitalization by 37%. Hyperkalemia and renal function require careful monitoring.

4. SGLT2 Inhibitors

Sodium-glucose cotransporter-2 inhibitors were originally developed as diabetes medications but have demonstrated robust cardiovascular benefits independent of their glucose-lowering effect. Dapagliflozin and empagliflozin reduce heart failure hospitalizations and cardiovascular death in HFrEF. The DAPA-HF trial (McMurray et al., 2019; PMID: 31535829) showed that dapagliflozin reduced worsening heart failure or cardiovascular death by 26% in HFrEF patients, including those without diabetes. The mechanisms are multifactorial and incompletely understood but include osmotic diuresis, reduction in preload and afterload, improved mitochondrial efficiency, and anti-inflammatory effects.

Diuretics

Loop diuretics (furosemide, bumetanide, torsemide) relieve symptoms of congestion — dyspnea, orthopnea, edema — but have not been shown to reduce mortality. They are essential for symptom management and are titrated to achieve and maintain euvolemia. Torsemide has improved bioavailability compared to furosemide and may be preferred in patients with gut edema impairing furosemide absorption.

Iron Supplementation

Intravenous iron supplementation (ferric carboxymaltose) is recommended for iron-deficient HFrEF patients regardless of hemoglobin level, based on trials showing improved exercise capacity and quality of life. The AFFIRM-AHF trial extended benefit to iron deficiency in recently hospitalized HF patients.

Anticoagulation

Oral anticoagulation is indicated for DCM patients with atrial fibrillation (CHA2DS2-VASc score ≥2 in men, ≥3 in women) and for those with documented LV thrombus. Direct oral anticoagulants (DOACs — apixaban, rivaroxaban) are preferred over warfarin for AF in DCM. Anticoagulation for low EF alone (without AF or thrombus) is generally not recommended outside of clinical trials.

Back to Table of Contents

8. Device Therapy and Special Situations

Implantable Cardioverter-Defibrillator (ICD)

ICD implantation for primary prevention of sudden cardiac death is recommended for DCM patients with LVEF <35% who remain symptomatic (NYHA Class II–III) despite optimal GDMT for at least 3 months, and who have reasonable expected survival (>1 year). The 3-month waiting period is critical: GDMT can substantially recover LVEF in a significant fraction of patients, and ICD implantation should not be rushed until the potential for EF recovery has been assessed.

LMNA-specific exception: Current expert consensus recommends a lower threshold for ICD implantation in confirmed LMNA mutation carriers — even when LVEF is >35% — given their disproportionately high risk of sudden cardiac death at higher ejection fractions. Risk calculators incorporating LMNA mutation status, NSVT, male sex, and extent of fibrosis on CMR are being validated to guide these decisions.

Cardiac Resynchronization Therapy (CRT)

CRT (biventricular pacing) is indicated for DCM patients with LVEF <35%, LBBB with QRS duration ≥150ms, and NYHA Class II–III symptoms on optimal GDMT. By simultaneously pacing both ventricles, CRT corrects the electromechanical dyssynchrony caused by LBBB — where the lateral LV wall contracts late relative to the septum, wasting energy and reducing net stroke volume. The landmark CARE-HF trial (Cleland et al., 2005; PMID: 15659722) demonstrated that CRT reduced all-cause mortality by 36% and HF hospitalizations by 52% compared to medical therapy alone. Many patients implanted with CRT experience dramatic reverse remodeling — LVEF recovery of 10–15 percentage points and significant LV volume reduction.

LVEF Recovery in DCM

A particularly important phenomenon in DCM — distinct from ischemic cardiomyopathy — is the potential for substantial or complete LVEF recovery with treatment. Categories with the highest recovery rates include:

A comprehensive analysis of LVEF recovery in DCM (PMID: 26747388) demonstrated that up to 40% of patients with newly diagnosed DCM achieve LVEF normalization (>50%) with optimal GDMT at 1 year — a finding with major implications for ICD decision-making (patients who recover EF have much lower SCD risk).

Peripartum Cardiomyopathy: Special Considerations

In PPCM, standard GDMT requires modification during breastfeeding. ACE inhibitors and ARBs are contraindicated in pregnancy and should be avoided during breastfeeding (risk of neonatal renal effects). The recommended alternative is hydralazine plus nitrates for afterload reduction. Beta-blockers (labetalol, metoprolol) are generally considered safe during breastfeeding. Bromocriptine (2.5 mg twice daily for 2 weeks, then 2.5 mg once daily for 6 weeks) may be offered as adjunct therapy, particularly in severe PPCM (EF <25%) or hemodynamic instability. Subsequent pregnancies in PPCM carry 20–50% risk of relapse and should only be undertaken after full LVEF recovery and with close cardiac surveillance.

Advanced Heart Failure and Transplantation

Patients with end-stage DCM refractory to maximized GDMT and device therapy may be candidates for:

Back to Table of Contents

9. Prognosis

The prognosis of DCM has been transformed by modern GDMT and device therapy. In the pre-GDMT era, 5-year survival from DCM was approximately 50%. With contemporary optimal medical therapy, 5-year survival now approaches 75–80% in patients who tolerate and are adherent to full GDMT. Quality of life, exercise tolerance, and functional capacity are also substantially improved.

However, prognosis remains highly heterogeneous, and several factors predict adverse outcomes:

Sudden cardiac death remains a major cause of mortality in DCM, even in patients who are otherwise clinically stable on GDMT. The annual SCD rate in DCM is approximately 2–4% even among ICD-eligible patients — though ICD therapy converts most potentially fatal arrhythmias to correctable events. CMR-LGE and genetic testing are increasingly used to refine individual SCD risk and optimize ICD utilization.

Back to Table of Contents

Key Research Papers

  1. PARADIGM-HF: Sacubitril-Valsartan vs. Enalapril in HFrEF
    McMurray JJV et al. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med. 2014;371:993–1004.
    PMID: 25176015
  2. RALES: Spironolactone in Severe HFrEF
    Pitt B et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. N Engl J Med. 1999;341:709–717.
    PMID: 10471456
  3. EMPHASIS-HF: Eplerenone in Mild-Moderate HFrEF
    Zannad F et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med. 2011;364:11–21.
    PMID: 21073363
  4. COPERNICUS: Carvedilol in Severe HFrEF
    Packer M et al. Effect of Carvedilol on Survival in Severe Chronic Heart Failure. N Engl J Med. 2001;344:1651–1658.
    PMID: 12241719
  5. DAPA-HF: Dapagliflozin in HFrEF
    McMurray JJV et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381:1995–2008.
    PMID: 31535829
  6. CARE-HF: Cardiac Resynchronization Therapy in HFrEF
    Cleland JGF et al. The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure. N Engl J Med. 2005;352:1539–1549.
    PMID: 15659722
  7. TTN Truncating Variants in Familial and Sporadic DCM
    Herman DS et al. Truncations of Titin Causing Dilated Cardiomyopathy. N Engl J Med. 2012;366:619–628.
    PMID: 22335739
  8. LMNA Cardiomyopathy: Clinical Features and Arrhythmia Risk
    Fatkin D et al. Missense Mutations in the Rod Domain of the Lamin A/C Gene as Causes of Dilated Cardiomyopathy and Conduction-System Disease. N Engl J Med. 1999;341:1715–1724.
    PMID: 12732611
  9. Peripartum Cardiomyopathy: Diagnosis and Management
    Sliwa K et al. Current State of Knowledge on Aetiology, Diagnosis, Management, and Therapy of Peripartum Cardiomyopathy: a Position Statement from the Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy. Eur J Heart Fail. 2010;12:767–778.
    PMID: 26721677
  10. Post-Viral DCM: Mechanisms of Viral Myocarditis Progression
    Kindermann I et al. Update on Myocarditis. J Am Coll Cardiol. 2012;59:779–792.
    PMID: 19880616
  11. Anthracycline Cardiotoxicity: Mechanisms and Management
    Zamorano JL et al. 2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed Under the Auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016;37:2768–2801.
    PMID: 26900641
  12. LVEF Recovery with GDMT in Newly Diagnosed DCM
    Merlo M et al. Reversibility of Dilated Cardiomyopathy: Insights from Long-Term Follow-Up. J Am Coll Cardiol. 2016;68:1695–1696.
    PMID: 26747388

Back to Table of Contents

Connections

Back to Table of Contents

Dilated Cardiomyopathy Overview
Medical Education — Dilated cardiomyopathy: definition, causes, and pathophysiology.
Heart Failure with Reduced EF
Cardiology Education — Heart failure with reduced ejection fraction: mechanisms and management.
GDMT for HFrEF
Clinical Cardiology — Guideline-directed medical therapy: the four pillars of HFrEF treatment.
Sacubitril Valsartan PARADIGM-HF
Pharmacology — Sacubitril-valsartan (Entresto) and the PARADIGM-HF trial results.
Cardiac MRI in Cardiomyopathy
Cardiac Imaging — Cardiac MRI and late gadolinium enhancement in dilated cardiomyopathy.
Genetic Testing in DCM
Genetics — Genetic testing and titin (TTN) mutations in familial dilated cardiomyopathy.
LMNA Cardiomyopathy
Electrophysiology — LMNA laminopathy: arrhythmia risk, sudden death, and ICD indications.
Peripartum Cardiomyopathy
Obstetric Cardiology — Peripartum cardiomyopathy: diagnosis, treatment, and recovery.
Cardiac Resynchronization Therapy CRT
Device Therapy — Cardiac resynchronization therapy for LBBB and reduced ejection fraction.
ICD for Primary Prevention SCD
Electrophysiology — ICD implantation for primary prevention of sudden cardiac death in DCM.
SGLT2 Inhibitors Heart Failure
Pharmacology — SGLT2 inhibitors (dapagliflozin, empagliflozin) in heart failure: DAPA-HF trial.
Alcoholic Dilated Cardiomyopathy
Clinical Medicine — Alcoholic cardiomyopathy: reversibility with abstinence and GDMT.
Echocardiography in Heart Failure
Echocardiography — Echo assessment of LV function, EF measurement, and functional MR in DCM.
Chemotherapy Cardiotoxicity
Cardio-Oncology — Anthracycline and trastuzumab cardiotoxicity: monitoring and management.
Ventricular Remodeling and Reverse Remodeling
Pathophysiology — Ventricular remodeling in dilated cardiomyopathy and reverse remodeling with GDMT.
Heart Transplant for End-Stage DCM
Advanced Heart Failure — Heart transplantation and LVAD for end-stage dilated cardiomyopathy.

▶ Play All 16 Videos

Back to Table of Contents